| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypersensitivity | D006967 | 22 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Urination Disorders | D014555 | 9 associated lipids |
| Arterial Occlusive Diseases | D001157 | 12 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Leukemia, Erythroblastic, Acute | D004915 | 41 associated lipids |
| Vision Disorders | D014786 | 10 associated lipids |
| Multiple Myeloma | D009101 | 13 associated lipids |
| Osteochondrodysplasias | D010009 | 3 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Hematologic Diseases | D006402 | 3 associated lipids |
| Muscular Dystrophies | D009136 | 10 associated lipids |
| Osteoporosis | D010024 | 12 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Kidney Diseases | D007674 | 29 associated lipids |
| Hematuria | D006417 | 13 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mieles L et al. | Interaction between FK506 and clotrimazole in a liver transplant recipient. | 1991 | Transplantation | pmid:1721250 |
| Yabuuchi H et al. | Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin. | 1991 | Transplant. Proc. | pmid:1703718 |
| First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. | 1991 | Transplant. Proc. | pmid:1721253 | |
| Goto T et al. | FK 506: historical perspectives. | 1991 | Transplant. Proc. | pmid:1721254 |
| Ochiai T et al. | Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. | 1991 | Transplant. Proc. | pmid:1721255 |
| Farghali H et al. | A biochemical and 31P-NMR investigation of the effect of FK 506 and cyclosporine pretreatment on immobilized hepatocytes perifused with ethanol. | 1991 | Transplant. Proc. | pmid:1721284 |
| Farghali H et al. | FK 506 modulates D-galactosamine-induced hepatitis in rats. | 1991 | Transplant. Proc. | pmid:1721285 |
| Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
| Francavilla A et al. | The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. | 1991 | Transplant. Proc. | pmid:1721287 |
| Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
| Matsuura T et al. | Beneficial immunosuppressive effect of combined use of FK 506 and cyclosporine assessed by proliferative responses of cloned human T cells. | 1991 | Transplant. Proc. | pmid:1721316 |
| Jiang H et al. | Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. | 1991 | Transplant. Proc. | pmid:1721317 |
| Yagihashi A et al. | The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721318 |
| Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
| Takaya S et al. | Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. | 1991 | Transplant. Proc. | pmid:1721348 |
| Morel P et al. | Liver retransplantation in adults: overall results and determinant factors affecting the outcome. | 1991 | Transplant. Proc. | pmid:1721349 |
| Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
| Alessiani M et al. | CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721351 |
| McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
| Alessiani M et al. | Infections in adult liver transplant patients under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703345 |
| Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
| Starzl TE et al. | Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. | 1991 | Transplant. Proc. | pmid:1703351 |
| Wagner K et al. | Effect of FK 506 on excretion of urinary enzymes in rats. | 1991 | Transplant. Proc. | pmid:1721379 |
| Prasad SJ et al. | In vitro effects of cyclosporine and FK 506 on the renal cortex. | 1991 | Transplant. Proc. | pmid:1721380 |
| Yamada K et al. | Short-term FK 506-induced morphological changes in rat kidneys. | 1991 | Transplant. Proc. | pmid:1721381 |
| Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
| Moutabarrik A et al. | In vitro FK 506 kidney tubular cell toxicity. | 1991 | Transplant. Proc. | pmid:1721383 |
| Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
| Tze WJ et al. | Long-term survival of islet allografts in diabetic rats treated with FK 506. | 1991 | Transplant. Proc. | pmid:1721411 |
| Wang X et al. | Intraportal FK 506 improves intrahepatic islet allograft survival. | 1991 | Transplant. Proc. | pmid:1721412 |
| Ohtsuka S et al. | The effect of short-term FK 506 therapy on pancreas transplantation in rats. | 1991 | Transplant. Proc. | pmid:1721413 |
| Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| Holechek MJ | Medication review: FK 506. | 1991 | ANNA J | pmid:1708982 |
| Michnick SW et al. | Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. | 1991 | Science | pmid:1709301 |
| Hasegawa S et al. | FK 506 and cyclosporine: effects and side effects in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721443 |
| Wada H et al. | Dose response to FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721444 |
| Lin CY et al. | Effects of FK 506 on the biochemical markers in canine lung allograft rejection. | 1991 | Transplant. Proc. | pmid:1721445 |
| Propper DJ et al. | Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. | 1991 | Transplant. Proc. | pmid:1721446 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Sakai K et al. | The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents. | 1991 | Brain Res. | pmid:1723023 |
| Weaver JL et al. | Comparison of the in vitro and biophysical effects of cyclosporine A, FK-506, and mycophenolic acid on human peripheral blood lymphocytes. | 1991 | Immunopharmacol Immunotoxicol | pmid:1723084 |
| Burres NS et al. | Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. | 1991 | J. Antibiot. | pmid:1723403 |
| Nielsen JB et al. | Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. | 1991 | Biochemistry | pmid:2043618 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |